A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML-Reference-Cited by-同舟云学术

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Published:2022-09-14 Issue:11 Volume:36 Page:2739-2742
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Mekinian Arsene^ORCID,Zhao Lin Pierre^ORCID,Chevret Sylvie,Desseaux Kristell,Pascal Laurent,Comont Thibaut,Maria Alexandre,Peterlin Pierre,Terriou Louis,D’Aveni Piney Maud,Gourin Marie-Pierre^ORCID,Vey Norbert^ORCID,Rauzy Odile Beyne,Grobost Vincent,Bezanahary Holy,Dimicoli-Salazar Sophie,Banos Anne,Wickenhauser Stefan,De Renzis Benoit,Durot Eric^ORCID,Natarajan-Amé Shanti,Voillat Laurent,Chermat Fatiha,Lemaire Karine,Jachiet Vincent,Himberlin Chantal,Thépot Sylvain,Diaz Jose Miguel Torregrosa,Frenzel Laurent,Gyan Emmanuel^ORCID,Denis Guillaume^ORCID,Hirsch Pierre,Kosmider Olivier^ORCID,Ades Lionel^ORCID,Fain Olivier,Fenaux Pierre

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01698-8.pdf

Reference15 articles.

1. Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology. 2016;55:291–300.

2. Zhao L-P, Boy M, Azoulay C, Clappier E, Sébert M, Amable L, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021;35:2720–4.

3. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383:2628–38.

4. Zhao L-P, Schell B, Sébert M, Kim R, Lemaire P, Boy M, et al. Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. Leukemia. 2021;35:2731–3.

5. Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021;137:3591–4.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review;Leukemia Research;2024-11

2. Mise en rémission par allogreffe de cellules souches hématopoïétiques d’une péri artérite noueuse associée à un syndrome myélodysplasique réfractaire à l’azacytidine;La Revue de Médecine Interne;2024-08

3. Long‐term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome;HemaSphere;2024-07-30

4. Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis;Bone Marrow Transplantation;2024-07-26

5. Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia;Leukemia & Lymphoma;2024-07-14